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CREPT and p15RS are two recently identified homologous proteins that regulate cell proliferation in an opposite way and are 
closely related to human cancer development. Both CREPT and p15RS consist of an N-terminal RPR domain and a C-terminal 
domain with high sequence homology. The transcription enhancement by CREPT is attributed to its interaction with RNA 
polymerase II (Pol II). Here we provide biochemical and structural evidence to support and extend this molecular mechanism. 
Through fluorescence polarization analysis, we show that the RPR domains of CREPT and p15RS (CREPT-RPR and 
p15RS-RPR) bind to different Pol II C-terminal domain (CTD) phosphoisoforms with similar affinity and specificity. We also 
determined the crystal structure of p15RS-RPR. Sequence and structural comparisons with RPR domain of Rtt103, a homolog 
of CREPT and p15RS in yeast, reveal structural basis for the similar binding profile of CREPT-RPR and p15RS-RPR with Pol 
II CTD. We also determined the crystal structure of the C-terminal domain of CREPT (CREPT-CTD), which is a long rod-like 
dimer and each monomer adopts a coiled-coil structure. We propose that dimerization through the C-terminal domain enhances 
the binding strength between CREPT or p15RS with Pol II by increasing binding avidity. Our results collectively reveal the 
respective roles of N-terminal RPR domain and C-terminal domain of CREPT and p15RS in recognizing RNA Pol II. 
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Tumor development is highly related to uncontrolled cell 
growth [1], a process in which oncogenes and tumor sup-
pressor genes are both involved [2]. CREPT (cell-cycle re-
lated and expression-elevated protein in tumor, another 
name RPRD1B) and p15RS (p15INK4b-related sequence, 
another name RPRD1A), two recently identified genes, are 
a pair of highly related genes that have opposite functions in 
regulating cell proliferation [3,4]. The encoded protein of 
p15RS is related to p15INK4b, a cyclin-dependent kinase 
inhibitor, and its expression inhibits cell proliferation [3,5,6]. 
By contrast, CREPT protein promotes cell proliferation by 
enhancing transcription of cell cycle related genes including 
the CYCLIN D1 and is highly expressed in diverse human 
tumors [4]. The proposed molecular mechanism of tran-
scription enhancement by CREPT is the formation of a 
chromatin loop that recycles RNA polymerase II (Pol II) 
from the termination site to the promoter region of a target 
gene [4]. Interestingly, Rtt103, an ancestor of both CREPT 
and p15RS in yeast, was demonstrated to play an important 
role in the regulation of yeast growth [7]. Recently, Rtt103 
was also demonstrated to function in DNA damage response 
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[8].  
RNA Pol II has a unique C-terminal domain (CTD) in its 
largest subunit RPB1, which is composed of multiple tan-
dem repeated heptapeptides with the consensus sequence 
Tyr1-Ser2-Pro3-Thr4-Ser5-Pro6-Ser7 with up to 52 repeats 
in mammals [911]. Dynamic and reversible modification 
of the Pol II CTD is essential for the efficient and accurate 
completion of transcription cycle [12,13]. The different 
modification state of CTD, particularly in the positions of 
Ser2 and Ser5, is closely related to the coordination and 
recruitment of transcription and mRNA processing factors 
to RNA Pol II [1316]. In the early stage of transcription, 
Ser5 phosphorylation (Ser5P) recruits the mRNA capping 
enzymes [1719]. As RNA Pol II progresses into the elon-
gation phase, the level of Ser2 phosphorylation (Ser2P) in-
creases while the level of Ser5P decreases [16]. At the late 
stage of transcription, Ser2P is the most dominating modi-
fication form of CTD in RNA Pol II, leading to increased 
recruitment of factors responsible for cleavage and polyad-
enylation [14].  
Both CREPT and p15RS consist of an N-terminal RPR 
domain and a C-terminal domain with high sequence simi-
larity, with only significant sequence variations in the linker 
region connecting these two domains [4]. The RPR domain 
is reported in several RNA processing and transcription 
termination factors and functions as a classical RNA Pol II 
CTD binding domain [2023]. Rtt103, a homolog of 
CREPT and p15RS in yeast, functions as a transcription 
terminator and also contains a RPR domain [23]. It associ-
ates with Pol II in the termination region at the 3′-end of a 
gene with the RPR domain to trigger the transcription ter-
mination of a gene together with Rai1, which favors the 
torpedo model of transcription termination [7]. Biochemical 
and structural studies have shown that the RPR domain of 
Rtt103 directly binds to the Ser2P CTD of RNA Pol II [23]. 
Our recent study showed that CREPT physically interacts 
with RNA Pol II [4]. Chromatin immunoprecipitation (ChIP) 
experiment further indicated that CREPT associates with 
the 5′ promoter region of the CYCLIN D1 gene [4], which is 
different from Rtt103. Therefore, we proposed that CREPT 
might promote the recycling of RNA Pol II from the termi-
nator to the promoter region, which was supported by the 
chromosome conformation capture (3C) experiment show-
ing that CREPT promotes the formation of a chromatin loop 
[4].  
Although our previous study has shed light on the tran-
scription enhancement by CREPT, the molecular mecha-
nism underlying the opposite effects of CREPT and p15RS 
in cell proliferation remains elusive. Structural and bio-
chemical studies of the RPR domain and C-terminal domain 
in CREPT and p15RS have not been reported yet. In this 
study, we report the crystal structures of the N-terminal 
RPR domain of p15RS (p15RS-RPR) and the C-terminal 
domain of CREPT (CREPT-CTD).  
1  Materials and methods 
1.1  Protein expression and purification 
The coding sequences of human CREPT-RPR domain (res-
idues 1132) and p15RS-RPR domain (residues 1131) 
were cloned into pET22b vector with a C-terminal His tag. 
Escherichia coli BL21 (DE3) cells harboring expression 
constructs were grown at 37°C in LB medium containing 
100 mg L1 ampicillin. Expression of target proteins was 
induced by addition of isopropyl-β-D-1-thiogalactopyra- 
noside (IPTG) to a final concentration of 0.5 mmol L1 
when the cell A600 reached 0.60.8. After further incubation 
at 16°C overnight, the cells were pelleted and re-suspended 
in a lysis buffer (50 mmol L1 Tris-Cl, 500 mmol L1 NaCl, 
pH 8.0) and lysed by sonication. After centrifuged at 
20000×g at 4°C for 1 h, the supernatant was transferred 
onto a Ni-NTA column, and was washed extensively with 
washing buffer (50 mmol L1 Tris-Cl, 500 mmol L1 NaCl, 
20 mmol L1 imidazole, pH 8.0). The bound His-tagged 
CREPT-RPR and p15RS-RPR were eluted with elution 
buffer (50 mmol L1 Tris-Cl, 500 mmol L1 NaCl, 500 
mmol L1 imidazole, pH 8.0), and further purified with a 
Superdex-200 gel filtration column in a running buffer con-
taining 50 mmol L1 Tris-Cl (pH 8.0) and 500 mmol L1 
NaCl. CREPT-CTD domain (residues 177326) and its 
truncation form (residues 177280) used for multi-angle 
light scattering (MALS) analysis were expressed and puri-
fied in a similar manner with CREPT-RPR and p15RS-RPR, 
except the running buffer for Superdex-200 gel filtration 
column was changed into 50 mmol L1 Tris-Cl (pH 8.0) 
with 150 mmol L1 NaCl. 
CREPT-CTD domain (residues 177326) prepared for 
crystallization was cloned into pGEX-6P-1 and expressed as 
a fusion protein with an N-terminal GST tag. The fusion 
protein was expressed in Escherichia coli BL21 (DE3) in-
duced with 0.5 mmol L1 IPTG at 16°C. The cells were 
harvested and suspended with lysis buffer containing 50 
mmol L1 Tris-Cl (pH 8.0), 500 mmol L1 NaCl and      
2 mmol L1 DTT. After sonication, the lysate was centri-
fuged at 20000×g for 1 h, and the supernatant containing 
GST-CREPT-CTD was transferred to a Glutathione Se-
pharose 4B column. After extensive wash, the bound fusion 
protein was digested on column with 3C PreScission prote-
ase at 4°C. The released CREPT-CTD without GST tag was 
collected and further purified by gel filtration chromatog-
raphy using the Superdex-200 gel filtration column with 
running buffer containing 50 mmol L1 Tris-Cl (pH 8.0), 
500 mmol L1 NaCl and 5 mmol L1 DTT. 
1.2  Fluorescence polarization measurement 
N-terminally 5,6-carboxyfluorescein (FAM)-labeled un-
phosphorylated Ser2P, Ser5P and Ser7P CTD peptides were 
purchased from Scilight Biotechnology, LLC, China. Fluo-
rescence polarization experiments were performed in a 
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black 384 well assay plate (Corning, USA) and measure-
ments were carried out in a fluorescence spectrometer En-
Vision (PerkinElmer, USA) in assay buffer containing 50 
mmol L1 Tris-Cl (pH 8.0) and 500 mmol L1 NaCl at 25°C. 
Multiple titrations were performed using fixed concentra-
tions of unphosphorylated Ser2P, Ser5P or Ser7P CTD pep-
tides at 0.1 µmol L1 with increasing concentrations of 
CREPT-RPR or p15RS-RPR (0.5, 1, 2, 5, 10, 20, 50, 100 
and 150 µmol L1) in a final volume of 20 µL reaction mix-
ture. Triple repeats were set for each individual measure-
ment. Samples were mixed by centrifuging at 1000×g for 5 
min at 4°C before measuring. In the measurement, samples 
were excited with vertically polarized light at 477 nm, and 
both vertical and horizontal emission were recorded at 525 
nm. Data was analyzed by Origin8 and fitted to the sig-
moidal logistic function. 
1.3  Co-immunoprecipitation 
CREPT and different truncation plasmids were generated by 
inserting the PCR-amplified fragments into a pcDNA3.1- 
Myc vector. CREPT was also inserted into a pcDNA3.1- 
flag vector to obtain the plasmid used for common im-
munoprecipitation bait. HEK293T cells were plated in 60 
mm dishes the day before transfection. Plasmids (2 µg) were 
transfected. Cells were lysed 2436 h after transfection in 
900 µL of cell lysis buffer (50 mmol L1 Tris-Cl, 150 mmol 
L1 NaCl, 50 mmol L1 NaF, 0.5% NP-40, pH 7.5) with 
protease inhibitors to prepare whole cell lysates. Lysates 
were mixed with anti-Myc and protein G-agarose beads and 
incubated at 4°C overnight. Immunoprecipitants and 5% of 
lysates were analyzed by immunoblotting for the indicated 
proteins. 
1.4  Multiple-angle light scattering (MALS) 
The molecular masses of CREPT-CTD and CREPT- 
CTD_177-280 in solution were determined by MALS using 
the DAWN HELEOSTM II 18-angle static light-scattering 
system (Wyatt Technology, USA), connected to an Agilent 
HPLC, and hooked up with a WTC SEC column (Wyatt 
Technology, USA). The system was first equilibrated with 
buffer containing 50 mmol L1 Tris-Cl (pH 8.0) and 150 
mmol L1 NaCl for more than 12 h. The equilibrated system 
was then calibrated with BSA at a concentration of 1 mg 
mL1. CREPT-CTD and CREPT-CTD_177-280 were pre-
pared in the aforementioned process and concentrated to 1 
mg mL1. Samples were injected to MALS analyzer at a 
flow rate of 0.5 mL min1 at 16°C. The molecular mass was 
calculated using ASTRA5.3.4.14 software (Wyatt Tech-
nology, uSA). 
1.5  Crystallization and data collection 
Proteins were prepared as described above. For p15RS-RPR, 
protein was concentrated to 23 mg mL1 in 50 mmol L1 
Tris-Cl (pH 8.0), 500 mmol L1 NaCl and 5 mmol L1 DTT. 
Crystals were grown at 18°C by vapor diffusion in sitting 
drops composed of equal volumes of protein and reservoir 
solution containing 2.2 mol L1 DL-Malic acid, 0.1 mol L1 
Bis-Tris propane, pH 7.0. For CREPT-CTD, protein with a 
concentration of 16 mg mL1 in the same buffer of 
p15RS-RPR domain was subjected to grow crystals. Crys-
tals were grown at 18°C by vapor diffusion in hanging drop 
with the reservoir buffer containing 28% PEG3350, pH 5.2. 
Crystals were frozen in liquid nitrogen with cryoprotectant 
(well solution plus 20% (v/v) glycol) before data collection. 
Diffraction data were collected at the BL17U beam line of 
the Shanghai Synchrotron Research Facility. Diffraction 
data were indexed, integrated and scaled with the program 
HKL2000 [25] and the statistics are listed in Table 1. 
1.6  Structural determination and refinement 
The structure of p15RS-RPR domain was determined by the 
molecular replacement method with program PHASER [26], 
and the search model is Rtt103-RPR NMR structures (PDB  
Table 1  Crystallographic data collection and refinement statistics 
 p15RS-RPR CREPT-CTD 
Data collection   
Beamline SSRF BL17U SSRF BL17U 
Wavelength 1.000 Å 1.000 Å 
Space group P21 P21 
Cell dimensions   
a, b, c (Å) 43.7, 47.3, 68.0 33.3, 55.7, 84.5 
, ,  () 90.0, 100.2, 90.0 90.0, 92.9, 90.0 
Resolution (Å) 50–2.00 (2.05–2.00) 50–2.80 (2.95–2.80) 
Rmerge (%) 8.6 (33.3) 8.4 (59.7) 
I/σI 20.1 (5.1) 6.8 (1.8) 
Completeness (%) 99.8 (100) 98.6 (99.2) 
Redundancy 3.7 (3.7) 2.9 (3.0) 
   
Refinement   
Resolution (Å) 30.3–2.00 42.2–2.80 
Number of reflections 18187 14346 
Rwork/Rfree (%) 17.4/21.4 24.0/29.0 












r.m.s. deviations   
Bond lengths (Å) 0.007 0.011 
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code 2KM4). After we collected the native diffraction data 
of CREPT-CTD, the structure of RPRD1B C-terminal do-
main was released (PDB code 4FLA), which is the same 
protein as CREPT-CTD. We therefore utilized it directly to 
determine the structure of CREPT-CTD using the molecular 
replacement method with program PHASER [26]. Structure 
refinement and model building were conducted with pro-
grams PHENIX and COOT, respectively [27,28]. The qual-
ity of the model was checked with program PROCHECK 
[29]. 
2  Results 
2.1  CREPT and p15RS recognize RNA Pol II CTD 
phosphoisoforms similarly 
We initially hypothesized that the opposite effects of 
CREPT and p15RS in the regulation of cell proliferation 
might result from their different binding specificity and af-
finity with RNA Pol II CTD. This hypothesis was supported 
by previous studies showing that the RPR domains from 
different transcription factors have different preferred CTD 
phosphoepitopes [2023]. It has been documented that ma- 
jor phosphorylation sites on RNA Pol II CTD are on Ser2,  
Ser5 and Ser7 [15,23], and the smallest functional unit of 
RNA Pol II CTD in in vitro biochemical studies has been 
defined as two consecutive heptad peptides [21,24]. There-
fore, we compared the binding affinities of CREPT-RPR 
and p15RS-RPR for a panel of synthetic diheptad CTD pep-
tides with different phosphoepitopes (Figure 1A) by fluo-
rescence polarization. In this experiment, the CREPT-RPR 
(residues 1–132) and p15RS-RPR (residues 1131) with a 
C-terminal six histidine tag were both expressed in 
BL21(DE3) bacteria and purified with Nickel resin fol-
lowed by size-exclusion chromatography. Both RPR do-
mains are monomeric in solution (Figure S1 in Supporting 
Information). 
Our fluorescence polarization analysis showed that 
CREPT-RPR and p15RS-RPR bound to the Ser2P RNA Pol II 
CTD with similar affinities of 12.3 and 13.7 µmol L1, re-
spectively (Figure 1B). Both RRP domains bound to un-
phosphorylated and Ser7P RNA Pol II CTD much weaker 
with ~36 fold decreased affinities (Figure 1B). CREPT- 
RPR and p15RS-RPR showed the weakest binding with 
Ser5P RNA Pol II CTD. The p15RS-RPR bound to Ser5P 
RNA Pol II CTD with an affinity of less than 1 mmol L1,  
 
 
Figure 1  Fluorescence polarization-based measurement of the binding affinities of CREPT-RPR and p15RS-RPR to diheptad CTD phosphopeptides. A, 
Schematic diagram of diheptad CTD peptides used in this study. Sequence is shown at the top, and serine phosphorylation sites are marked with orange 
circles. B, Titration curves of CREPT-RPR (top left) and p15RS-RPR (top right) domains into 0.1 μmol L1 FAM-labeled unphosphorylated (black), Ser2P 
(red), Ser5P (blue) and Ser7P (cyan) CTD diheptad repeat peptide and calculated affinities (bottom). ND, not detectable.  
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and CREPT-RPR did not bind to Ser5P RNA Pol II CTD in 
fluorescence polarization experiment (Figure 1B). These 
results suggest that CREPT-RPR and p15RS-RPR exhibit 
similar binding specificity and affinity with RNA Pol II 
CTD, and Ser2P RNA Pol II CTD is the most preferred 
binding phosphoisoform. 
2.2  The structure of p15RS-RPR 
The crystal structure of p15RS-RPR was determined by the 
molecular replacement method and refined to a resolution of  
2.0 Å with Rwork of 17.4% and Rfree of 21.4% (Table 1). 
There are two molecules in an asymmetric unit in a 
sub-vertical orientation (Figure S2 in Supporting Infor-
mation). For each molecule, the structure identifies a com-
pact eight-helix bundle in a right-handed super-helical ar-
rangement (Figure 2A). The structure of p15RS-RPR is 
very similar to that of the yeast Rtt103-RPR domain with 
1.3 Å Cα r.m.s. deviation over the entire length of the poly-
peptide (Figure 2B). Amino acids in the hydrophobic core 
of p15RS-RPR and Rtt103-RPR are highly conserved in 
CREPT-RPR (Figure 2C), suggesting that CREPT-RPR 
 
 
Figure 2  Structure of the N-terminal RPR domain of p15RS (p15RS-RPR). A, Ribbon diagram representation of p15RS-RPR. B, Left panel shows the 
structural superimposition of p15RS-RPR (purple) and Rtt103-RPR (green). Right panel shows the interactions between Rtt103-RPR (green) and Ser2P CTD 
diheptad peptide (blue). Hydrogen-bonding and salt-bridge interactions are represented with yellow dotted lines. C, Amino acid sequence alignment of the 
RPR domains of p15RS, CREPT and Rtt103. Helices are indicated as cylinders above the alignment. Residues involved in hydrophobic core packing are 
marked with a triangle. Residues involved in RNA Pol II CTD binding revealed in the complex structure of Rtt103-RPR with peptide are marked with a dot. 
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domain also adopts a similar eight-helix structure with su-
per-helical arrangement.  
A previously reported complex structure of Rtt103-RPR 
with a diheptad Pol II CTD peptide with two Ser2 phos-
phorylation positions showed that the peptide binds along 
helices 2, 4, and 7 of Rtt103-RPR [23], which are also the 
most structurally conserved helices between Rtt103-RPR 
and p15RS-RPR (Figure 2B). Rtt103 residues binding to the 
peptide are highly conserved in p15RS-RPR and CREPT- 
RPR (Figure 2B and C). The direct salt-bridge interaction 
between Arg108 in helix 7 of Rtt103 and the phosphate 
group of Ser2 position (Figure 2B) was suggested to be 
critical in determining the preference for Ser2P Pol II CTD 
over other phosphoisoforms [23]. This arginine residue is 
conserved in this position in p15RS-RPR and CREPT-RPR 
(Figure 2C). We expect that this arginine residue in 
p15RS-RPR and CREPT-RPR will also bind to the phos-
phate group of Ser2, which is critical in determining their 
binding preference among different phosphopeptides. In-
deed, our fluorescence polarization analysis showed that 
p15RS-RPR and CREPT-RPR bind preferentially to Ser2P 
Pol II CTD (Figure 1). 
2.3  The structure of CREPT C-terminal domain 
Compared with the N-terminal RPR domain, no structure 
information is available for the C-terminal domain of 
CREPT and p15RS. We purified the CREPT-CTD (residues 
177–326) expressed in BL21 (DE3) bacteria and determined 
its structure at 2.8 Å resolution with Rwork of 24.0% and Rfree 
of 29.0% (Table 1). CREPT-CTD is an elongated, rod- 
shaped dimer, with dimensions of ∼30×30×140 Å (Figure 
3A). Each monomer in the structure consists of residues 
Thr177 to Leu305, and other residues at the C-terminal tail 
were not built due to weak electron densities. The N-   
terminal region of CREPT-CTD monomer consists of three 
short helices α1 (Thr177-Ala190), α2 (Gly193-Ala202), and 
α3 (Val211-Lys216) that run approximately half the length 
of the rod (Figure 3A and B). After a short loop of three 
residues, a very long helix α4 (Lys220-Ile297) runs the en-
tire length of the rod (Figure 3A and B). The helix α4 is 
continuous and has the shape of a long arch (Figure 3A). 
Two CREPT-CTD monomers interlock to form a symmetric 
dimer. The N termini of the two monomers (helix α1) are 
close together at the middle of the rod, and the C termini are 
at the opposite ends of the rod, far away from each other 
(Figure 3A). 
2.4  Inter-chain interactions in CREPT-CTD 
We further analyzed the inter-chain interactions of 
CREPT-CTD. Upon interlocked into a dimer, the long and 
symmetric binding interface between two CREPT-CRD 
monomers (A and B) have a very large buried surface of 
~6400 Å2 (3200 Å2 each monomer). The two antiparallel 
longest α4 helices running the entire length of the dimer 
form a coiled-coil structure, which forms the frame of the 
dimer (Figure 4A). Due to the symmetric nature of the 
binding interface, here we only describe the interacting res-
idues in the half of the interface. Hydrophobic residues in-
volved in the interactions between the α4 helices include 
Val230(A), Leu237(A), Tyr240(A), Leu244(A), Leu248(A), 
Leu258(A), Tyr261(B), Leu276(B), Tyr279(B), Leu283(B), 
Val286(B), and Val289(B) (Figure 4A). Another significant 
characteristic of interactions between these two α4 helices is 
the surface charge complementary, including Asp231(A)- 
Arg290(B), Glu247(A)-Lys272(B), and Arg252(A)- Glu273 
(B) salt-bridge interactions (Figure 4A). At the two far ends 
of the dimer, the C-terminal tail of the α4 helix further in-
teracts with the short α3 helix of another monomer, forming  
 
 
Figure 3  Structure of CREPT-CTD and sequence alignment between CREPT-CTD and p15RS-CTD. A, Ribbon diagram representation of CREPT 
C-terminal domain (CREPT-CTD) dimer. B, Sequence alignment of CREPT-CTD and p15RS-CTD. Conserved residues are marked with light blue back-
ground, and helices in CREPT-CTD are indicated as cylinders above the alignment. 
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Figure 4  Inter-chain interactions in CREPT-CTD dimer. A, Packing between two α4 helices provides the frame work of the dimer. Other α helices are 
removed for a clear view of the interactions. Salt-bridge interactions are represented with black dotted lines. B, The interactions at the far ends of the rod-like 
dimer. C, Interactions between two α1 helices at the middle of the rod-like dimer. 
a short triple-helix structure (Figure 4B). At this region, 
residues Val211(B), Leu214(B), Ile217(B), Ala223(B), and 
Leu226(B) form a hydrophobic cluster with Val289(A), 
Leu293(A), Ile297(A), and Leu300(A) (Figure 4B). At the 
middle of the dimer, the N-terminal α1 helices of monomers 
A and B have an antiparallel interaction, and the interacting 
hydrophobic residues include Leu180, Ile181, and Leu184 
from each monomer (Figure 4C). 
We proposed that the full-length CREPT might form a 
dimer mediated by the association of its CTD domain be-
cause the N-terminal RPR domain is monomeric in solution 
(Figure S1A in Supporting Information). To test this hy-
pothesis, we measured the interaction of Flag-CREPT with 
Myc-CREPT expressed in 293T cells with immunoprecipi-
tation method. In particular, we checked the effects of 
C-terminal truncations of Myc-CREPT on the association 
with full-length Flag-CREPT as the crystal structure shows 
that the C-terminal end of the α4 helix is involved in the 
CREPT-CTD dimer formation (Figure 4B). The IP results 
indicated that the C-terminal truncated Myc-CREPT mu-
tants CREPT_1-285, CREPT_1-290, CREPT_1-295 and 
CREPT_1-300 deleting residues from 286, 291, 296 and 
301 amino acid positions retained the interaction with 
Flag-CREPT, as strong as the interaction of full length 
Myc-CREPT with Flag-CREPT (Figure 5A). Deleting the 
C-terminal region from Val286 did not interfere with the 
interaction between CREPT monomers, but deleting five 
more residues from Gln281 to Arg285 abolished the inter- 
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Figure 5  C-terminal deletion from Gln281 interrupts the aggregation of 
CREPT. A, Co-immunoprecipitation experiment between full-length 
CREPT-Flag and different truncation forms of CREPT-Myc. HEK293T 
cells were transfected with Flag-tagged full-length CREPT and different 
truncations of Myc-tagged CREPT. Cell lysates were immunoprecipitated 
using an anti-Myc antibody and the precipitants were detected with an 
anti-Flag antibody. B, MALS assay shows that the molecular weight of 
CREPT-CTD is ~33 kD, which is consistent with the dimer formation; 
while CREPT-CTD deleting from Gln281 (CREPT-CTD_177-280) exists 
mostly in monomer form (~14 kD), with a little part of dimer (~27 kD). 
action (Figure 5A). Considering the interaction between full 
length CREPT is mediated by the C-terminal domain, we 
further generated a CREPT-CTD C-terminal truncation de-
leting residues from Gln281 (CREPT-CTD_177-280). Mul-
tiple-angle light scattering (MALS) analysis showed that 
most of CREPT-CTD_177-280 is monomer in solution, 
while the wild type CREPT-CTD is dimer (Figure 5B). This 
further supported that the C-terminal end of α4 helix is im-
portant for the dimer formation of CREPT-CTD, which 
mediates the interaction between full-length CREPT. 
3  Discussion 
CREPT is a recently identified oncogene that is highly ex-
pressed in different tumors [4]. It has been observed that 
CREPT promotes cell proliferation by enhancing the ex-
pression of cell-cycle-related genes [4]. On the other hand, 
the expression of p15RS, a homologous protein of CREPT, 
was reported to inhibit cell proliferation [3], functioning as 
an intrinsic inhibitor of Wnt signaling mediated transcrip-
tion [5]. CREPT and p15RS both contain an N-terminal 
RPR domain, which recognizes RNA Pol II CTD, and a 
C-terminal domain with unknown function. Interestingly, 
both domains of CREPT and p15RS share high sequence 
identities. In this study, we performed biochemical and 
structural studies on the RPR and C-terminal domains, try-
ing to figure out their respective roles in recognizing RNA 
Pol II CTD by CRETP of p15RS and explain the opposite 
function of CREPT and p15RS in regulating cell prolifera-
tion. 
Our results demonstrated that the N-terminal RPR do-
main of CREPT and p15RS are very similar in binding 
Ser2P Pol II CTD, with higher affinity than other Pol II 
CTD phosphoisoforms (Figure 1). Structural determination 
of p15RS RPR domain and comparison with yeast Rtt103 
RPR domain showed that critical residues for the interaction 
with Ser2P diheptapeptide are conserved in them, as well as 
in CREPT (Figure 2B and C), revealing a structural basis 
for the binding preference to Ser2P diheptapeptide by 
CREPT and p15RS. We previously have shown that 
CREPT is able to bind RNA Pol II at the promoter and ter-
minator regions of genes and proposed that it recycles the 
Pol II to the 5′ promoter region by a chromatin loop [4]. 
RNA Pol II at the late stage of transcription is modified by 
phosphorylation at Ser2 positions of RNA Pol II CTD, 
while Ser5P is the most dominating modification state of 
CTD before the late stage of transcription [10,13,15,17]. 
Our fluorescence polarization analysis showed that 
CREPT-RPR did not bind to the Ser5P diheptapeptide, even 
weaker than the binding with the unphosphorylated dihep-
tapetpide (Figure 1). Therefore, we proposed that CREPT 
might selectively associate with Ser2P CTD of RNA Pol II 
at the 3′ terminal end of a transcribing gene. Whether the 
preferred interaction of CREPT with Ser2P CTD of RNA 
Pol II would facilitate the formation of a chromatin loop by 
the association with 5′ promoter region remained to be ex-
amined. Currently, we are not clear about the molecular 
basis of the association of CREPT with 5′ promoter region 
of a gene. Since CREPT failed to associate with Ser5P CTD 
of RNA Pol II, which remains at a high level in the promot-
er region during the transcription initiation, we speculate 
that other proteins that could bind to DNA might associate 
with Ser5P CTD of RNA Pol II and CREPT simultaneously 
to regulate the status of RNA Pol II in the promoter region. 
The RPR domain has also been found in several RNA 
processing and transcription termination factors other than 
CREPT and p15RS [20,22,23]. The RPR containing pro-
teins additionally have other domains responsible for pro-
tein-protein and protein-RNA interactions such as Pcf11, 
Rtt103, and SCAF8. However, CREPT and p15RS contain 
only the RPR domain, except their conserved C-terminal 
domain without a high sequence homology with other pro-
teins. The structure of CREPT-CTD shows that C-terminal 
domain of CREPT forms a very long rod-like dimer, each 
monomer adopting a coiled-coil structure (Figure 3A). We 
analyzed the interactions between two CREPT-CTD do-
mains and found that the C-terminal residues from Gln281 
to Arg285 are critical for the dimer formation of the 
 Mei KR, et al.   Sci China Life Sci   January (2014) Vol.57 No.1 105 
CREPT-CTD in solution (Figure 5B), as well as for the in-
teraction between full length CREPT monomers (Figure 5A) 
when they associate together to form a dimer or other ag-
gregated forms in the cell. 
We searched the Dali server and identified some proteins 
containing a similar coiled-coil structure as the CREPT- 
CTD but with diverse functions (data not shown). The 
coiled-coil structure is a popular structural motif found in 
many proteins, structural similarity therefore is not able to 
provide further insights into the function of CTD in CREPT 
and p15RS. We propose that CREPT may form a dimer in 
the association with RNA Pol II. It is speculated that the 
CREPT-CTD dimer might directly enhance the interaction 
of CREPT with RNA Pol II. The N-terminal RPR domain 
functions as a monomer, supported by both biochemical 
data and the crystal structure (Figure S1A in Supporting 
Information; Figure 2A). The complex structure of 
Rtt103-RPR domain with Ser2P diheptapeptide suggests 
that the RPR domain monomer has one binding site for the 
peptide, especially for the Ser2P [23]. The RNA Pol II CTD 
consists of up to 52 heptapeptide repeats [11]. The 
full-length CREPT holds a very stable dimer in its 
C-terminal domain, and two N-terminal RPR domains are 
linked to the C-terminal dimer via a long linker (Figure 6). 
The flexibility of the linker enables the two RPR domains to 
interact with the RNA Pol II CTD with Ser2P individually 
with a similar affinity. The dimeric CREPT complex that 
has two Pol II CTD binding sites is expected to increase the 
binding avidity with Pol II CTD. 
The functional role of the RPR domain in direct associa-
tion with RNA Pol II CTD has been studied [2023]. Here 
we firstly report the dimer structure of CREPT C-terminal 
domain and propose that one function of CREPT-CTD di-
mer is to increase binding strength of CREPT with Pol II 
CTD (Figure 6). We expect that the RPR and C-terminal 
domains in p15RS would have similar functions because the 
highly conserved primary amino acid sequences in these 
two domains (Figure S3 in Supporting Information) and our 
MALS data showed that p15RS-CTD is dimer in solution 
(Figure S4 in Supporting Information). This raises an inter-
esting question still not answered: what is the molecular 
mechanism underlying the opposite function in regulating 
cell proliferation by CREPT and p15RS? Besides the pro-
posed role of increasing binding avidity, we cannot exclude 
that the similar C-terminal domains of CREPT and p15RS 
bind to different protein partners that would determine their  
 
 
Figure 6  A model of interaction between CREPT or p15RS dimer and 
RNA Pol II CTD. 
different functions in vivo. Another possibility resides in the 
linker region connecting the RPR to the C-terminal domain 
(Figure S3 in Supporting Information), which demonstrates 
quite diverse sequences in CREPT and p15RS.   
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Supporting Information 
Figure S1  Gel-filtration of CREPT-RPR (A) and p15RS-RPR (B). The coordinate graph on the top right of each figure is a plot of log molecular weight 
against elution volume of the column. Gel filtration standards (Bio-Rad) used in the experiment were vitamin B12 (1.3 kD), horse myoglobin (17 kD), 
chicken ovalbumin (44 kD), bovine gamma-globulin (158 kD), and bovine thyroglobulin (670 kD). Theoretical molecular weight of CREPT-RPR and 
p15RS-RPR monomer is 15.283 and 15.22 kD, respectively. Calculated molecular weight from gel filtration of CREPT-RPR and p15RS-RPR is 14.092 and 
14.628 kD, indicating that CREPT-RPR and p15RS-RPR are monomers. 
Figure S2  Two p15RS-RPR molecules in an asymmetric unit are in a sub-vertical orientation. 
Figure S3  Sequence alignment of human p15RS and CREPT. Red box indicates the long loop linking N-terminal RPR domain and C-terminal domain 
(CTD) which shows high diversity. Residues 281 to 285 important for CREPT dimer formation are indicated. 
Figure S4  MALS analysis shows that the molecular weight of p15RS-CTD in solution is around 35 kD (red curve), indicating that it is a dimer in solution. 
The molecular weight of CREPT-CTD dimer (purple curve) in solution is also around 35 kD. 
The supporting information is available online at life.scichina.com and link.springer.com. The supporting materials are 
published as submitted, without typesetting or editing. The responsibility for scientific accuracy and content remains entirely 
with the authors. 
 
